Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$65.34 USD
+0.54 (0.83%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.32 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.34 USD
+0.54 (0.83%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.32 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Zacks News
Cytokinetics (CYTK): An Off-the-Radar Potential Winner
by Zacks Equity Research
Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for Cytokinetics (CYTK) and that now might be an interesting buying opportunity.
5 Profitable Stocks to Buy for Great Returns
by Zacks Equity Research
Net income ratio gives us the exact profit level of a company and reflects the percentage of net income to total sales revenue.
New Strong Buy Stocks for December 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
3 Biotech Stocks to Turn the Tide This Earnings Season
by Zacks Equity Research
The biotech sector has strong fundamentals, and healthy product pipelines.
4 Biotech Stocks Looking Good this Earnings Season
by Zacks Equity Research
the market sentiment seems to be improving driven by upgraded guidance, product approvals and encouraging pipeline updates.
5 Stocks Rocketing to New Highs
by David Bartosiak
These 5 stocks are breaking out to new highs on good volume